Facioscapulohumeral Dystrophy clinical trials at University of California Health

1 research study open to eligible people

Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
open to eligible people ages 16-70
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
at UC Irvine

Last updated: September 26, 2025